2786 completed, 910 recruiting, 838 unknown, 783 terminated. 2934 Phase 2, 2211 Phase 1, 573 Phase 3, 539 Not applicable, 133 Early Phase 1.
Follow Lymphoma, Non-Hodgkin: new trials by email Literature Review of Lymphoma, Non-Hodgkin trials Research Report on Lymphoma, Non-Hodgkin
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| FLASH Pilot Phase 1 Safety Study IntraOp Mobetron UHDR, Linac - Cutaneous Lymphoma | Not applicable | Not yet recruiting | Lesley A. Jarvis | 10 | 2029-10-31 | 2026-05-27 |
| Family-Focused Study to Support Medication for Opioid Use Disorder FamilyCHESS, Standard of Care - Opioid Use Disorder, Opioid Use Disorder, Moderate | Not applicable | Not yet recruiting | University of Wisconsin, Madison | 338 | 2027-08-31 | 2026-07-07 |
| Astragalus for Symptomatic Alleviation in High-grade Lymphoma Astragalus, Placebo - High-grade Lymphoma | Phase 3 | Not yet recruiting | Bnai Zion Medical Center | 60 | 2027-08-01 | 2026-09-30 |
| Multi-CAR-T Cells Targeting B Cell Lymphomas 4SCAR19 and 4SCAR20/22/70/PSMA/13/79b/GD2 - B Cell Lymphoma (BCL) | Phase 1 / Phase 2 | Not yet recruiting | Shenzhen Geno-Immune Medical Institute | 11 | 2027-06-01 | 2026-08-26 |
| Study of Sugemalimab (or Placebo) Plus PGemOx Regimen in Participants With Extranodal NK/T-Cell Lymphoma Sugemalimab, Placebo, Pegaspargase - Extranodal NK/T-cell Lymphoma | Phase 3 | Not yet recruiting | CStone Pharmaceuticals | 150 | 2027-06-01 | 2026-05-27 |
| Prizloncabtagene Autoleucel (Prizlon-cel) for the Treatment of Relapsed or Refractory Large B-cell Lymphoma Post FDA Approved CAR T-cell Therapy Prizloncabtagene Autoleucel - Large B Cell Lymphoma, LBCL | Phase 2 | Not yet recruiting | AbelZeta Inc. | 55 | 2027-05-01 | 2026-10-15 |
| Genetically Engineered Cells (BAFFR-CAR T Cells) for the Treatment of Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia and B-cell Lymphoblastic Lymphoma Autologous BAFFR-targeting CAR T Cells, Biospecimen Collection, Bone Marrow Aspiration - Recurrent B Acute Lymphoblastic Leukemia, Recurrent B Lymphoblastic Lymphoma | Phase 1 | Not yet recruiting | City of Hope Medical Center | 16 | 2027-04-17 | 2026-08-11 |
| Phase I Safety Clinical Trial of Anti-CD19 CAR-T Therapy COL01 for the Treatment of Adults With Relapsed or Refractory B-cell Lymphoid Neoplasms: First-in-human Administration, COLIBRI. CAR-T anti-CD19 COL01 - Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia, Lymphoid Malignancies | Phase 1 | Not yet recruiting | GUSTAVO SALGUERO | 12 | 2027-04-01 | 2026-10-20 |
| Testing the Effect of Teclistamab on Recurrent Plasmablastic Lymphoma Biospecimen Collection, Computed Tomography, Positron Emission Tomography - Recurrent Plasmablastic Lymphoma, Refractory Plasmablastic Lymphoma | Phase 1 | Recruiting | National Cancer Institute (NCI) | 30 | 2027-03-26 | 2026-10-20 |
| Microbiome Intervention for CAR-T Optimization and Response (MICRO-CART) Live Biotherapeutic Product (LBP), Placebo - Lymphoma, B-Cell, Multiple Myeloma | Phase 1 | Not yet recruiting | University of Chicago | 32 | 2027-02-23 | 2026-10-13 |
| Randomized Phase 2 Study Of Epcoritamab Vs Watch And Wait InPatients With Previously Untreated Low Tumor Burden FollicularLymphoma Epcoritamab, Observation - Randomized, Phase 2 | Phase 2 | Not yet recruiting | M.D. Anderson Cancer Center | 40 | 2027-02-12 | 2026-09-23 |
| Safety and Efficacy of Early Second Infusion of Axi-cel Based on ctDNA for R/R Large B - Cell Lymphoma Infusion of Axicabtagene Ciloleucel - Relapsed/Refractory Diffuse Large B-cell Lymphoma | Phase 1 / Phase 2 | Recruiting | Zhujiang Hospital | 15 | 2027-02-01 | 2025-03-30 |
| Autologous IC-Nine, CD30 CAR, and Constitutive IL7R Expressing EBVST for CD30 Lymphoma (ANCILE-30) Autologous C7R.CD30-CAR-EBVSTs - Diffuse Large B-Cell Lymphoma (DLBCL), Hodgkin Lymphoma | Phase 1 | Not yet recruiting | The Methodist Hospital Research Institute | 21 | 2027-01-15 | 2026-07-27 |
| A Study Comparing a New Drug (Surovatamig) With Standard Radiotherapy With or Without Rituximab in Adults With Limited Stage Nodal Follicular Lymphoma Surovatamig, Involved Site Radiotherapy (ISRT), Involved-Site Radiotherapy (ISRT) + Rituximab - Follicular Lymphoma | Phase 3 | Not yet recruiting | Australasian Leukaemia and Lymphoma Group | 140 | 2027-01-12 | 2026-09-30 |
| Testing the Safety of Anti-Cancer Drug, CX-5461 (Pidnarulex), in Treating Lymphoma With Specific Changes in the MYC Gene Biopsy Procedure, Biospecimen Collection, Computed Tomography - Burkitt Lymphoma, Double-Expressor Lymphoma | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 50 | 2027-01-11 | 2026-10-14 |
| Belinostat in Combination With Azacitidine or Pralatrexate for the Treatment of Relapse or Refractory T-cell Lymphoma Azacitidine, Belinostat, Biospecimen Collection - Recurrent Anaplastic Large Cell Lymphoma, Recurrent Enteropathy-Associated T-Cell Lymphoma | Phase 1 | Not yet recruiting | City of Hope Medical Center | 40 | 2027-01-03 | 2026-07-09 |
| Characterization of the Microbiome in Cutaneous T Cell Lymphoma Skin Lesions Before and After Use of APR-TD011® (RLF-TD011®) Spray Solution APR-TD011 (RLF-TD011) - Cutaneous T Cell Lymphoma | Early Phase 1 | Not yet recruiting | Northwestern University | 30 | 2027-01-01 | 2026-05-01 |
| A Study of Topical Duvelisib in Participants With Early-stage Mycosis Fungoides Duvelisib - Mycosis Fungoides, Cutaneous T-cell Lymphoma | Phase 1 | Not yet recruiting | SecuraBio | 30 | 2027-01-01 | 2026-07-20 |
| GRACE: A Phase 1/2a Study of VTRU200 in Relapsed/Refractory AML, High-risk MDS, DLBCL Post CART Failure and Advanced Solid Tumors VTRU200 - Acute Myeloid Leukemia, Diffuse Large B Cell Lymphoma (DLBCL) | Phase 1 / Phase 2 | Not yet recruiting | Vitruviae | 108 | 2027-01-01 | 2026-08-06 |
| Depletion of CD45RA Positive Naive T Cells for the Prevention of Graft Versus Host Disease in Older Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia or Myelodysplastic Syndrome Allogeneic CD34+-enriched and CD45RA-depleted PBSCs, Biospecimen Collection, Bone Marrow Aspiration - Acute Biphenotypic Leukemia, Acute Leukemia | Phase 2 | Not yet recruiting | Fred Hutchinson Cancer Center | 52 | 2027-01-01 | 2026-09-14 |
Showing 20 of 6383. Sign in to see all of them.
Lymphoma, Follicular (1873) · Lymphoma, Large B-Cell, Diffuse (1824) · Lymphoma (1399) · Lymphoma, Mantle-Cell (1209) · Leukemia, Lymphocytic, Chronic, B-Cell (1054) · Burkitt Lymphoma (971) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (910) · Lymphoma, B-Cell, Marginal Zone (863) · Hodgkin Disease (861) · Lymphoma, B-Cell (775) · Recurrence (605) · Multiple Myeloma (574) · Lymphoma, T-Cell, Cutaneous (550) · Leukemia (512)
Neoplasms by Histologic Type (6362) · Hemic and Lymphatic Diseases (6303) · Immune System Diseases (6269) · Immunoproliferative Disorders (6266) · Lymphatic Diseases (6265) · Lymphoproliferative Disorders (6206) · Neoplasms (6106) · Lymphoma (4984) · Lymphoma, B-Cell (2322) · Hematologic Diseases (1946) · Pathological Conditions, Signs and Symptoms (1827) · Pathologic Processes (1726) · Disease Attributes (1622) · Leukemia, Lymphoid (1541)
Rituximab (1077) · Cyclophosphamide (848) · Vincristine (424) · Doxorubicin (383) · Prednisone (381) · Etoposide (337) · Lenalidomide (261) · fludarabine (256) · Cytarabine (241) · fludarabine phosphate (225) · Filgrastim (208) · Dexamethasone (199) · Bendamustine Hydrochloride (188) · Methotrexate (188) · Peripheral Blood Stem Cell Transplantation (164)
National Cancer Institute (NCI) (301) · M.D. Anderson Cancer Center (174) · Memorial Sloan Kettering Cancer Center (128) · Fred Hutchinson Cancer Center (104) · City of Hope Medical Center (90) · Ruijin Hospital (89) · Hoffmann-La Roche (76) · Novartis Pharmaceuticals (64) · Fondazione Italiana Linfomi - ETS (58) · Celgene (56) · Mayo Clinic (52) · Sun Yat-sen University (51) · Northwestern University (46) · Pfizer (44) · Alliance for Clinical Trials in Oncology (41)
United States (3431) · China (1131) · France (618) · Italy (518) · United Kingdom (447) · Spain (431) · Germany (420) · Canada (393) · Australia (345) · South Korea (309) · Belgium (253) · Poland (234) · Japan (197) · Netherlands (178) · Israel (164)
Ajay Gopal (15)
PMID 34515338, PMID 41671463, PMID 32632956, PMID 32499241, PMID 35622074, PMID 31401903, PMID 40550489, PMID 39319495, PMID 26373676, PMID 27282998, PMID 40802906, PMID 23834234, PMID 30125215, PMID 32816215, PMID 34398557, PMID 35787017, PMID 19238148, PMID 31050355, PMID 33288485, PMID 34780125, PMID 34806163, PMID 39563886, PMID 39813680, PMID 17242396, PMID 20660832, PMID 20679620, PMID 22510871, PMID 23065508, PMID 23524640, PMID 23753028, PMID 25113753, PMID 25381051, PMID 27209293, PMID 28054442, PMID 30518502, PMID 30620669, PMID 30770362, PMID 32589970, PMID 32770353, PMID 33883258, PMID 34310745, PMID 34687939, PMID 35882475, PMID 37486616, PMID 38502198, PMID 38551807, PMID 40156952, PMID 40195173, PMID 40472301, PMID 42699559
2023 (69), P30CA033572 (69), P30CA015704 (50), 2015 (39), 2017 (38), 2016 (34), 2018 (32), U10CA032102 (31), P30CA015083 (27), U10CA180886 (27), P30CA043703 (26), 2019 (23), U10CA031946 (23), 2014 (22), P30CA016672 (21)